Drugs approved for treatment of liver cancer

Share This Post

Dec 2021: Following drugs are approved as on date for treatment of liver cancer. Please check prescribing information before taking the drug.

Atezolizumab
Avastin (Bevacizumab)
Bevacizumab
Cabometyx (Cabozantinib-S-Malate)
Cabozantinib-S-Malate
Cyramza (Ramucirumab)
Infigratinib Phosphate
Keytruda (Pembrolizumab)
Lenvatinib Mesylate
Lenvima (Lenvatinib Mesylate)
Nexavar (Sorafenib Tosylate)
Nivolumab
Opdivo (Nivolumab)
Pemazyre (Pemigatinib)
Pembrolizumab
Pemigatinib
Ramucirumab
Regorafenib
Sorafenib Tosylate
Stivarga (Regorafenib)
Tecentriq (Atezolizumab)
Truseltiq (Infigratinib Phosphate)

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea

Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love

admin May 3, 2023

Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love